FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts

Abstract Group 3 tumors account for 28% of medulloblastomas and have the worst prognosis. FTY720, an immunosuppressant currently approved for treatment of multiple sclerosis, has shown antitumor effects in several human cancer cell lines. We hypothesized that treatment with FTY720 (fingolimod) would...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Evan F. Garner, Adele P. Williams, Laura L. Stafman, Jamie M. Aye, Elizabeth Mroczek-Musulman, Blake P. Moore, Jerry E. Stewart, Gregory K. Friedman, Elizabeth A. Beierle
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/60d3b17a2b504ab498e8b0462588e830
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:60d3b17a2b504ab498e8b0462588e830
record_format	dspace
spelling	oai:doaj.org-article:60d3b17a2b504ab498e8b0462588e8302021-12-02T11:40:54ZFTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts10.1038/s41598-018-25263-52045-2322https://doaj.org/article/60d3b17a2b504ab498e8b0462588e8302018-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-25263-5https://doaj.org/toc/2045-2322Abstract Group 3 tumors account for 28% of medulloblastomas and have the worst prognosis. FTY720, an immunosuppressant currently approved for treatment of multiple sclerosis, has shown antitumor effects in several human cancer cell lines. We hypothesized that treatment with FTY720 (fingolimod) would decrease tumorigenicity in medulloblastoma patient-derived xenografts (PDXs). Three Group 3 medulloblastoma PDXs (D341, D384 and D425) were utilized. Expression of PP2A and its endogenous inhibitors I2PP2A and CIP2A was detected by immunohistochemistry and immunoblotting. PP2A activation was measured via phosphatase activation kit. Cell viability, proliferation, migration and invasion assays were performed after treatment with FTY720. Cell cycle analysis was completed using flow cytometry. A flank model using D425 human medulloblastoma PDX cells was used to assess the in vivo effects of FTY720. FTY720 activated PP2A and led to decreased medulloblastoma PDX cell viability, proliferation, migration and invasion and G1 cell cycle arrest in all three PDXs. FTY720 treatment of mice bearing D425 medulloblastoma PDX tumors resulted in a significant decrease in tumor growth compared to vehicle treated animals. FTY720 decreased viability, proliferation, and motility in Group 3 medulloblastoma PDX cells and significantly decreased tumor growth in vivo. These results suggest that FTY720 should be investigated further as a potential therapeutic agent for medulloblastoma.Evan F. GarnerAdele P. WilliamsLaura L. StafmanJamie M. AyeElizabeth Mroczek-MusulmanBlake P. MooreJerry E. StewartGregory K. FriedmanElizabeth A. BeierleNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-10 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Evan F. Garner Adele P. Williams Laura L. Stafman Jamie M. Aye Elizabeth Mroczek-Musulman Blake P. Moore Jerry E. Stewart Gregory K. Friedman Elizabeth A. Beierle FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts
description	Abstract Group 3 tumors account for 28% of medulloblastomas and have the worst prognosis. FTY720, an immunosuppressant currently approved for treatment of multiple sclerosis, has shown antitumor effects in several human cancer cell lines. We hypothesized that treatment with FTY720 (fingolimod) would decrease tumorigenicity in medulloblastoma patient-derived xenografts (PDXs). Three Group 3 medulloblastoma PDXs (D341, D384 and D425) were utilized. Expression of PP2A and its endogenous inhibitors I2PP2A and CIP2A was detected by immunohistochemistry and immunoblotting. PP2A activation was measured via phosphatase activation kit. Cell viability, proliferation, migration and invasion assays were performed after treatment with FTY720. Cell cycle analysis was completed using flow cytometry. A flank model using D425 human medulloblastoma PDX cells was used to assess the in vivo effects of FTY720. FTY720 activated PP2A and led to decreased medulloblastoma PDX cell viability, proliferation, migration and invasion and G1 cell cycle arrest in all three PDXs. FTY720 treatment of mice bearing D425 medulloblastoma PDX tumors resulted in a significant decrease in tumor growth compared to vehicle treated animals. FTY720 decreased viability, proliferation, and motility in Group 3 medulloblastoma PDX cells and significantly decreased tumor growth in vivo. These results suggest that FTY720 should be investigated further as a potential therapeutic agent for medulloblastoma.
format	article
author	Evan F. Garner Adele P. Williams Laura L. Stafman Jamie M. Aye Elizabeth Mroczek-Musulman Blake P. Moore Jerry E. Stewart Gregory K. Friedman Elizabeth A. Beierle
author_facet	Evan F. Garner Adele P. Williams Laura L. Stafman Jamie M. Aye Elizabeth Mroczek-Musulman Blake P. Moore Jerry E. Stewart Gregory K. Friedman Elizabeth A. Beierle
author_sort	Evan F. Garner
title	FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts
title_short	FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts
title_full	FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts
title_fullStr	FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts
title_full_unstemmed	FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts
title_sort	fty720 decreases tumorigenesis in group 3 medulloblastoma patient-derived xenografts
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/60d3b17a2b504ab498e8b0462588e830
work_keys_str_mv	AT evanfgarner fty720decreasestumorigenesisingroup3medulloblastomapatientderivedxenografts AT adelepwilliams fty720decreasestumorigenesisingroup3medulloblastomapatientderivedxenografts AT lauralstafman fty720decreasestumorigenesisingroup3medulloblastomapatientderivedxenografts AT jamiemaye fty720decreasestumorigenesisingroup3medulloblastomapatientderivedxenografts AT elizabethmroczekmusulman fty720decreasestumorigenesisingroup3medulloblastomapatientderivedxenografts AT blakepmoore fty720decreasestumorigenesisingroup3medulloblastomapatientderivedxenografts AT jerryestewart fty720decreasestumorigenesisingroup3medulloblastomapatientderivedxenografts AT gregorykfriedman fty720decreasestumorigenesisingroup3medulloblastomapatientderivedxenografts AT elizabethabeierle fty720decreasestumorigenesisingroup3medulloblastomapatientderivedxenografts
_version_	1718395518375165952

FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts

Ejemplares similares